Highlighting that there is no uniform path to leukemic transformation, whole genome sequencing of a single patient with post-MF AML demonstrated a JAK2-mutated dominant founder clone in chronic phase, a JAK2/ASXL1/RUNX1/IDH1-mutated subclone upon AML transformation, and a JAK2/ASXL1-mutated disease at relapse. This evidence concerns the gene ASXL1 and acute myeloid leukemia.